LLY

751.49

+0.07%↑

JNJ

153.95

+1.34%↑

UNH

323.91

+3.75%↑

ABBV

184.94

-0.06%↓

NVO

68.4

+2.97%↑

LLY

751.49

+0.07%↑

JNJ

153.95

+1.34%↑

UNH

323.91

+3.75%↑

ABBV

184.94

-0.06%↓

NVO

68.4

+2.97%↑

LLY

751.49

+0.07%↑

JNJ

153.95

+1.34%↑

UNH

323.91

+3.75%↑

ABBV

184.94

-0.06%↓

NVO

68.4

+2.97%↑

LLY

751.49

+0.07%↑

JNJ

153.95

+1.34%↑

UNH

323.91

+3.75%↑

ABBV

184.94

-0.06%↓

NVO

68.4

+2.97%↑

LLY

751.49

+0.07%↑

JNJ

153.95

+1.34%↑

UNH

323.91

+3.75%↑

ABBV

184.94

-0.06%↓

NVO

68.4

+2.97%↑

Search

Xenon Pharmaceuticals Inc

Avatud

SektorTervishoid

31.7 2.16

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

30.19

Max

31.52

Põhinäitajad

By Trading Economics

Sissetulek

-2.9M

-66M

Aktsiakasum

-0.84

Töötajad

316

EBITDA

-3.8M

-77M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+76.32% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-179M

2.7B

Eelmine avamishind

29.54

Eelmine sulgemishind

31.7

Uudiste sentiment

By Acuity

67%

33%

349 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. mai 2025, 20:40 UTC

Omandamised, ülevõtmised, äriostud

FedEx Names CEO, Chairman for Planned Freight Spinoff

20. mai 2025, 00:00 UTC

Peamised uudised

America's Fiscal Situation Threatens the Good Mood on Wall Street -- WSJ

19. mai 2025, 23:48 UTC

Market Talk

Nikkei May Rise as Fears About Moody's U.S. Downgrade Ease -- Market Talk

19. mai 2025, 23:43 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

19. mai 2025, 23:22 UTC

Peamised uudised

Crypto Billionaire Accused of Defrauding Creditors, Propelling Industry's 2022 Collapse -- WSJ

19. mai 2025, 22:33 UTC

Market Talk

Uranium Buyers Could Accelerate Restocking -- Market Talk

19. mai 2025, 22:16 UTC

Omandamised, ülevõtmised, äriostud

Yuexiu Property to Use Divestment Proceeds for Business Development Purposes

19. mai 2025, 22:16 UTC

Omandamised, ülevõtmised, äriostud

Yuexiu Property to Sell Stake for CNY4.15B

19. mai 2025, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Yuexiu Property to Sell Stake to China Resources Land

19. mai 2025, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Yuexiu Property to Sell 65% Stake in Beijing Haizhen Real Estate

19. mai 2025, 22:02 UTC

Tulu

Trip.com Group 1Q Rev $1.9B >TCOM

19. mai 2025, 22:02 UTC

Tulu

Trip.com Group 1Q Adj EPS 82c >TCOM

19. mai 2025, 22:02 UTC

Tulu

Trip.com Group 1Q EPS 84c >TCOM

19. mai 2025, 21:58 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

19. mai 2025, 21:58 UTC

Market Talk

Global Equities Roundup: Market Talk

19. mai 2025, 21:58 UTC

Market Talk

Automakers to Raise Prices by End of June, Toyota COO Says -- Market Talk

19. mai 2025, 21:50 UTC

Peamised uudised
Tulu

Home Depot's Earnings Could Mirror a Sluggish Housing Market -- Barrons.com

19. mai 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

19. mai 2025, 20:48 UTC

Peamised uudised

Home Depot's Earnings Could Mirror a Sluggish Housing Market -- Barrons.com

19. mai 2025, 20:21 UTC

Omandamised, ülevõtmised, äriostud

FedEx: R. Brad Martin, Vice Chmn of the FedEx Corp. Bd of Directors, Agreed to Serve as Chmn of the Bd of FedEx Freight >FDX

19. mai 2025, 20:21 UTC

Omandamised, ülevõtmised, äriostud

FedEx: Both Appointments Will Be Effective Upon Completion of the Previously Announced Separation of FedEx Freight From FedEx Corp. >FDX

19. mai 2025, 20:21 UTC

Omandamised, ülevõtmised, äriostud

FedEx: Plans for the Spinoff, Which Is Expected to Occur by June 2026, Remain on Track >FDX

19. mai 2025, 20:21 UTC

Omandamised, ülevõtmised, äriostud

FedEx: Announces Leadership for Independent FedEx Freight Co Upon Separation

19. mai 2025, 20:21 UTC

Omandamised, ülevõtmised, äriostud

FedEx: John A. Smith, Oper Chief, U.S. and Canada, of Federal Express, Has Been Selected as Pres and CEO of FedEx Freight >FDX

19. mai 2025, 20:20 UTC

Peamised uudised

Major U.S. Stock Indexes Finish Higher; Dollar Falls -- WSJ

19. mai 2025, 20:15 UTC

Omandamised, ülevõtmised, äriostud

U.S. Steel Stock Rises on Report of Better Nippon Offer. Why Trump Could Say 'Yes.' -- Barrons.com

19. mai 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

19. mai 2025, 19:59 UTC

Peamised uudised

JPMorgan CEO Dimon Still Intends to Step Down in Next Few Years. 'It's Up to the Board.' -- Barrons.com

19. mai 2025, 19:58 UTC

Market Talk

Estonia Redirects Ships After Russia Detains Greek Tanker -- Market Talk

19. mai 2025, 19:52 UTC

Market Talk

Imports Accelerate at Southern California Ports -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

76.32% tõus

12 kuu keskmine prognoos

Keskmine 54.57 USD  76.32%

Kõrge 65 USD

Madal 42 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

17 ratings

17

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Neutral Evidence

Sentiment

By Acuity

349 / 382 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.